EGFR and lung cancer: Previous studies revealed lung cancer patients with good PS had better outcomes when receiving chemotherapies or first-line EGFR-TKIs.[26, 32, 33] Consistent with previous studies, our study revealed patients with bone metastases had better survival if they had a good PS.[22] We assume patients with poor PS are not appropriate for chemotherapies, radiotherapies, or palliative surgery; experience more myelosuppression; are more likely to succumb to non-cancer death; and consequently have dismal outcomes.[34]